Loading
Extracellular Vesicles in Disease · Journal article
Materials Today Bio · August 1, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a proof-of-concept study using engineered extracellular vesicles to deliver a peptidoglycan hydrolase (GH15) into intracellular Staphylococcus aureus in vitro and in zebrafish larvae. The work demonstrates feasibility of targeted delivery and bacterial killing in artificial systems but provides no efficacy, toxicity, or dose–response data needed for clinical assessment.
In vitro cell culture and in vivo larval model proof-of-concept study. Human umbilical vein endothelial cells (HUVECs), macrophages, and larval zebrafish (Danio rerio); all experimentally infected with Staphylococcus aureus. Intervention: Engineered extracellular vesicles encapsulating peptidoglycan hydrolase GH15 (CHAPGH15_SH3bALE1) with αvβ3 integrin-targeting biotinylated antibody on the surface.
Engineered EVs with αvβ3 integrin-targeting antibodies successfully delivered GH15 into infected endothelial cells and macrophages in vitro GH15-loaded EVs eliminated intracellular S. aureus in HUVECs and macrophages as well as in infected zebrafish larvae in vivo GH15 enzyme combines CHAP endopeptidase and SH3b cell-binding domains and demonstrates bactericidal activity against multidrug-resistant S. aureus
No toxicity, off-target effects, or immunogenicity assessment described Zebrafish larval model does not predict mammalian pharmacokinetics or immune responses
This is early-stage research on a novel delivery platform for antimicrobial enzymes. No efficacy, toxicity, pharmacokinetics, or dose data are provided; substantial development is required before any clinical evaluation.
Proof-of-concept study in cell culture and larval models demonstrating engineered EV-mediated delivery of a peptidoglycan hydrolase; lacks mammalian efficacy data, toxicity assessment, and clinical translation pathway.
As stated by the source record.
This is early-stage research on a novel delivery platform for antimicrobial enzymes. No efficacy, toxicity, pharmacokinetics, or dose data are provided; substantial development is required before any clinical evaluation.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Bacterial infectious diseases remain a major global health threat. Although antibiotics are effective, their therapeutic success is declining due to increasing antimicrobial resistance. In addition, some hospital‑associated pathogens, such as Staphylococcus aureus, may persist inside host cells during antibiotic treatment. Peptidoglycan hydrolases (PGHs), such as bacteriophage‑derived endolysins, represent a promising class of alternative antimicrobials due to their rapid bacteriolytic activity and low risk of resistance emergence. Recent advances in genetic engineering have further enhanced their specificity and bactericidal efficacy. One such engineered enzyme, CHAPGH15_SH3bALE1 (GH15), combines the CHAP endopeptidase domain of LysGH15 with the SH3b cell‑binding domain from ALE1 and efficiently kills multidrug‑resistant S. aureus. However, the therapeutic use of PGHs is naturally restricted by limited stability in vivo and inefficient penetration into host cells. To overcome these challenges, we encapsulated GH15 in extracellular vesicles (EVs), naturally occurring nanovesicles that mediate intracellular cargo delivery. EVs were isolated from genetically modified C51 donor cells expressing glycosylphosphatidylinositol‑linked avidin (GPI‑Av) for further surface functionalization. To promote targeted delivery, EVs were equipped with a biotinylated antibody targeting αvβ3 integrin, which is upregulated on infected host cells. The engineered EVs successfully delivered GH15 into infected cells and eliminated intracellular S. aureus in endothelial cells (HUVECs) and in macrophages in vitro, as well as in infected zebrafish larvae in vivo. Overall, our study demonstrates the potential of EVs as targeted delivery systems for encapsulated therapeutics, particularly for treating infections caused by intracellular bacteria.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.